An in vivo study suggested enhanced concentrations of synaptic dopamine in the brain of patients with schizophrenia (Kegeles et al., 2010); however, another in vitro study revealed lowered CHGB levels in the schizophrenia patients’ cerebrospinal fluid (Landén et al., 1999). The gene discussed is CHGB; the disease is schizophrenia.